FindTrial
Sign In

Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance

Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Induced by Steroid Treatment, Relative Physical Inactivity and High Calorie Diet

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01173978
Enrollment
10
Registered
2010-08-03
Start date
2010-04-30
Completion date
2010-07-31
Last updated
2011-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Deteriorated Glucose Homeostasis, Inactivity, Insulin Resistance

Keywords

Incretin hormones, Glucagon, Insulin/c-peptide, Plasma glucose, Insulin resistance, Deteriorated glucose homeostasis, Inactivity

Brief summary

The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals. The purpose of this study is to evaluate the insulinotropic affect of the incretin hormones in healthy individuals before and after a deterioration of the glucose homeostasis.

Detailed description

The incretin effect in patients with type two diabetes is reduced. The investigators have previously shown that it is possible to induce a defect in the incretin effect in healthy individuals. The purpose of this study is to evaluate the insulinotropic affect of the incretin hormones in healthy individuals before and after a deterioration of the glucose homeostasis. The evaluation is done by infusing GIP, GLP-1 or saline during hyperglycemic clamps.

Interventions

BEHAVIORALSteroid hormone

Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day

OTHERNo intervention

Sponsors

University of Copenhagen
CollaboratorOTHER
European Foundation for the Study of Diabetes
CollaboratorOTHER
Glostrup University Hospital, Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* Caucasians without type 2 diabetes mellitus * Normal OGTT (75 g of glucose) according to WHO's criteria * BMI 20-30 * Hemoglobin \> 8.0 mmol/l * Informed consent

Exclusion criteria

* Liver disease (ALAT \> 2 x normal level) * Nephropathy (s-creatinin \> 130 µM or albuminuria) * Relatives (parents/siblings) with T2DM * Medical treatment witch cannot be stopped for 12 hours

Design outcomes

Primary

MeasureTime frameDescription
Insulinotropic effect of incretin hormones12 daysMeasurements of the insulinotropic effect of incretin hormones before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity

Secondary

MeasureTime frameDescription
Plasma concentration of glucagon12 daysMeasurements of plasma concentration of glucagon before and after 12 days intervention with steroid treatment, high calorie diet and relative physical inactivity

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026